It is well known that relapse-associated mutations in ALL are specifically selected upon by chemotherapy, exemplified by mutations in KRAS, NRAS and PTPN11, which illustrates a chemotherapy driven selection mechanism for clonal evolution7. The gene discussed is KRAS; the disease is acute lymphoblastic leukemia.